Ligand Pharmaceuticals reported $50.38M in Sales Revenues for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Acorda Therapeutics ACOR:US USD 31.47M 2.04M
Amgen AMGN:US USD 6.84B 187M
Arrowhead Research ARWR:US USD 62.55M 30.97M
Baxter International BAX:US USD 3.89B 114M
Bristol Myers Squibb BMY:US USD 11.41B 188M
Clovis Oncology CLVS:US USD 30.66M 1.48M
Eli Lilly And LLY:US USD 7.3B 360.2M
Endo International Ordinary Shares ENDP:US USD 541.69M 27.42M
Gilead Sciences GILD:US USD 7.39B 347M
Glaxosmithkline GSK:US GBP 7.38B 453M
GlaxoSmithKline GSK:LN GBP 7.38B 453M
Karyopharm Therapeutics KPTI:US USD 33.58M 2.56M
Lannett LCI:US USD 80.89M 5.82M
Ligand Pharmaceuticals LGND:US USD 50.38M 15.71M
Merk MRK:US USD 13.83B 1.13B
Pfizer PFE:US USD 24.29B 1.65B
Sangamo Biosciences SGMO:US USD 27.23M 770K
Teva Pharmaceutical Industries TEVA:US USD 3.88B 289M